Utang jangka cendhak marang modal Zymeworks (ZYME)

The development of Zymeworks Inc. (ZYME) relies on the success of zanidatamab and funding from Jazz Pharmaceuticals. This chart reflects a current market value of 0.00. Protein supply chain security is ensured through partnerships with various contractors. Meanwhile, unique antibodies allow the company to exercise pricing power in licensing agreements, attracting significant investment into its research and development.

This ratio measures the proportion of liabilities maturing within one year relative to equity, determining liquidity risk and the degree of dependence on short-term debt financing. For Zymeworks Inc. (ZYME), which attracts multi-billion dollar licensing payments for innovative antibodies, the level of short-term borrowing relative to equity serves as an indicator of the balance between aggressive R&D development and the issuer's financial stability.